World Cervical Cancer Elimination Day: Prevention, Diagnosis, and Diagnostic Innovation

November 17 marks World Cervical Cancer Elimination Day, established by the World Health Organization with the ambitious goal of making cervical cancer a preventable and eliminable disease by 2030.

Cervical cancer is closely linked to persistent infection with human papillomavirus (HPV), one of the most common sexually transmitted infections.
That’s why primary prevention (vaccination) and secondary prevention (regular screening) are essential tools to reduce both incidence and mortality.

Eurospital’s Role in HPV Diagnostics

On the path toward eliminating cervical cancer, Eurospital reaffirms its commitment to supporting laboratories and healthcare professionals with reliable, precise, and scientifically validated diagnostic solutions.

Their tools, including the Neoplex HPV 29 Kit, based on multiplex Real-Time PCR technology, enables simultaneous detection of 29 HPV genotypes with varying oncogenic risk, ensuring fast and accurate results.

Thanks to these solutions, Eurospital contributes concretely to improving the quality of HPV screening, supporting early diagnosis and personalized patient management.
A future without cervical cancer is possible: research, prevention, and quality diagnostics are the keys to achieving it.